Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Review Article
Author Details :
Volume : 9, Issue : 4, Year : 2023
Article Page : 485-488
https://doi.org/10.18231/j.ijceo.2023.093
Abstract
A atresia of nasolacrimal duct which is congenital in nature causing lacrimation and mucous secretion from the eyes. Nasolacrimal duct atresia is the most common disorder of newborns showing symptoms of this condition around 6 to 20 percent. Generally symptoms shows after birth within few weeks with excessive tears and discharge from eye which may be present in single or both eye. Both upper and lower eyelids redness may result due to irritation by tears and eye discharge. Due to this condition it presents like a chronic unilateral or bilateral conjunctivitis.Observation and conservative treatment is the best treatment in infants and nasolacrimal probing is the best treatment option for children above one year of age. But the timing for probing is still under debatable. Other surgical invasive methods like intubation of silicon tube, dilation by balloon catheter and (DCR) dacryocystorhinostomy. So aim of this review study is provide an update on congenital NLD Atresia treatment.
Keywords: Congenital nasolacrimal duct atresia, Lacrimal sac, Mucous secretion, Tears.
How to cite : Medatwal A, Singhvi P, Medatwal R, Garg M, Treatment management of congenital nasolacrimal duct atresia: A review article. Indian J Clin Exp Ophthalmol 2023;9(4):485-488
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.